Vivus shares slide on downgrade; FDA puts off decision on AMAG's app for new Feraheme use;

@FiercePharma: Top news yesterday: Teva halts Israeli layoffs amid pressure from labor, gov't. Report | Follow @FiercePharma

@CarlyHFierce: Eisai to recruit 200 new sales reps for amped-up Belviq push. ICYMI yesterday | Follow @CarlyHFierce

> The FDA extended its review of AMAG Pharma's application for broader use of its anemia therapy, Feraheme, for three months. Report

> Vivus ($VVUS) shares slid after a Piper Jaffray analyst lowered his price target and cut his rating on the stock, after disappointing prescription numbers on its weight-loss drug Qsymia. Report

> The global vaccine alliance is rolling out a low-cost human papillomavirus (HPV) vaccine program, using discounted shots from Merck ($MRK) and GlaxoSmithKline ($GSK), in Laos this week. Report

> Most common tumors are driven by only a few gene mutations, according to a new study, which may help identify new uses for approved cancer drugs that target specific genetic changes. Report

> The FDA pulled an antibiotic from B. Braun Medical, cefepime, after vials were found to contain bits of metal, cotton and hair. Report | More from FiercePharmaManufacturing

Medical Device News

@FierceMedDev: Roche ekes out diagnostics growth as diabetes biz falters. More | Follow @FierceMedDev

@MarkHFierce: Another J&J hip lawsuit is settled. Will the company resolve the 11,000-plus suits that remain outstanding? Story | Follow @MarkHFierce

@MichaelGFierce: Trending from FierceDrugDelivery: Mini-pancreas grown from stem cells has implications for future delivery. Article | Follow @MichaelGFierce

> Roche will close 454 Life Sciences and stop making its gene sequencing tech. Item

> Wright buying implant outfit for $80M with eye on Europe. News

> Quest blames outside factors for lowering already diminished 2013 expectations. More

> Device tax repeal fight fails again as government funding bill avoids the issue. Article

Biotech News

@FierceBiotech: Industry Voices: Clinical trial transparency--time for some carrot as well as more stick? Feature | Follow @FierceBiotech

@JohnCFierce: Danish biotech Egalet pitches $69M IPO on Nasdaq. News | Follow @JohnCFierce

@DamianFierce: Fresh off a staggering FDA rejection, Wright is spending $80M on an implant outfit. Story | Follow @DamianFierce

@EmilyMFierce: AstraZeneca, Harvard's Wyss Institute partner to advance 'Organs-on-Chips' drug-testing tech. Item | Follow @EmilyMFierce

> Aragon begets Seragon as VCs bankroll $30M cancer drug spinoff. Article

> Roche: Forget mega-mergers, focus on a new round of blockbuster bolt-ons. Story

> Amarin shares shrivel after FDA experts spurn Vascepa. Item

> AstraZeneca, Amgen Crohn's drug runs into PhII 'logistical' snafu. Report

Pharma Manufacturing News

@EricPFierce: Another gut check for Amarin and its fish oil drug : panel votes against wider use. News | Follow @EricPFierce

> In turnabout, U.K. tells Wockhardt to recall 5 drugs. Report

> Federal case over drug shortage comes to an end. Story

> Teva reconsiders production cuts in Israel. Item

> B. Braun recalls product after organic particulate found. More

> Genzyme expanding U.S. plant opened last year. Article

Vaccines News

> Cost of rabies vaccine limiting use in Africa. Report

> Merck, Sanofi report on first vaccine in European pilot project. More

> IOM releases modeling software for vaccine prioritization. Item

> Novartis cuts jobs in California as eastward shift continues. More

> India to expand use of pentavalent vaccine after safety thumbs-up. Article

> U.K. court orders sisters to receive MMR vaccine. Story

And Finally... Working against your natural body clock causes "social jet lag," which increases the risk of a variety of health problems, including obesity, a researcher says. Report (sub. req.)